Atıf İçin Kopyala
Eskiler G. G., ÇEÇENER G., DİKMEN G., EGELİ Ü., TUNCA B.
CURRENT DRUG DELIVERY, cilt.16, sa.6, ss.511-529, 2019 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
16
Sayı:
6
-
Basım Tarihi:
2019
-
Doi Numarası:
10.2174/1567201816666190515105532
-
Dergi Adı:
CURRENT DRUG DELIVERY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.511-529
-
Anahtar Kelimeler:
Triple Negative Breast Cancer (TNBC), PARP inhibitors, Talazoparib (BMN 673), Solid Lipid Nanoparticles (SLNs), Apoptosis, cytotoxic effects, DRUG-DELIVERY-SYSTEMS, INHIBITOR BMN 673, PARP INHIBITOR, DNA-REPAIR, MULTIDRUG-RESISTANCE, SYNTHETIC LETHALITY, HIGHLY POTENT, CANCER, CYTOTOXICITY, PACLITAXEL
-
Bursa Uludağ Üniversitesi Adresli:
Evet
Özet
Objective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized.